Navigation Links
CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
Date:2/17/2012

WASHINGTON, Feb. 17, 2012 /PRNewswire/ -- The Consumer Healthcare Products Association (CHPA) today released the following statement regarding a new economic impact study that analyzed the potential economic consequences a prescription requirement for safe and effective cold and allergy medicines containing pseudoephedrine (PSE) would have on the state of Oklahoma. The study was conducted by the Economic Impact Group, LLC, and funded by a grant provided by the CHPA.

Some of the study's most compelling findings include the following impacts of a prescription requirement:  

  • An influx of more than 296,000 new doctor visits in Oklahoma, with costs reaching as much as $59 million in the state.
  • The productivity cost from missed days from work or school already accounts for an estimated $227 to $400 million from viral respiratory tract infections in Oklahoma.  These costs would climb considerably under a prescription requirement.

"The economic impact study in Oklahoma quantified what we already knew to be true: a prescription requirement for popular and reliable over-the-counter cold and allergy medicines will lead to higher healthcare costs for responsible consumers, lower productivity for Oklahoma businesses, and lost tax revenues for the state," said Scott Melville, president and CEO, CHPA. "Effectively reducing meth production in Oklahoma is a critically important goal, but it's important that methods employed to achieve that goal do not burden law-abiding Oklahomans with significant and unnecessary costs."

www.chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
2. Roche responds to announcement of IDEAL hepatitis C trial results
3. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
4. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
5. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
6. EPSScentral Responds to Pandemic Alert
7. Endologix Responds to Alleged Patent Infringement
8. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
9. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
10. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
11. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... study published in the Proceedings of the ... that showed when ibrutinib (IMBRUVICA ® ) was ... suppression of tumor growth was enhanced suggesting a ... hematologic cancers and solid tumors with the combination. ...
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... 2, 2011 Men who take non-steroidal anti-inflammatory drugs three ... times more likely to have erectile dysfunction compared to men ... Kaiser Permanente study published online in The Journal of ... trend toward this same finding, this observational study used electronic ...
... SILVER SPRING, Md., March 2, 2011 The U.S. ... that manufacture, distribute, or market certain unapproved prescription oral ... be legally marketed in the United States. ... cough, cold, and allergy drug products have not been ...
Cached Medicine Technology:Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 3FDA Prompts Removal of Unapproved Drugs From Market 2FDA Prompts Removal of Unapproved Drugs From Market 3
(Date:2/28/2015)... The World Scout League Commission (WSLC), an ... EMTs and firefighters, recently announced its decision to host ... raise charitable donations for age-related research. The five-kilometer race, ... held on March 29, 2015; registration will start at ... p.m. , To participate in the race, runners ...
(Date:2/27/2015)... Hispanics develop alcoholic liver disease (ALD), a common ... earlier than Whites/Caucasians or African Americans, according to a ... previous research indicated that Hispanics tend to have more ... published online in the journal Alcoholism: Clinical and Experimental ... pinpoint racial and ethnic disparities in the ages at ...
(Date:2/27/2015)... February 27, 2015 A new study ... correlation between men who cycle on a regular basis and ... the study suggests that the more hours per week a ... prostate cancer, leading to an increased importance on prostate cancer ... physicians to look more closely at patents’ risk factors for ...
(Date:2/27/2015)... Today, February 27th, is "Shine A Light On ... LXR Organics and Living Fuel, Inc. , ... awareness and promote prevention, rescue and restoration for people held ... IT Coalition, slavery is the 2nd largest global organized crime, ... countries around the world. Slavery includes bonded labor, forced labor, ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Altec ... LLP (BPW) has been chosen as their doc-link for ... GP, CRM and other complimentary solutions for their customers ... working with credit unions. Altec and BPW have worked ... doc-link’s integration to Dynamics GP. , “We are so ...
Breaking Medicine News(10 mins):Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... Metric Ton of CO2 ... in Emissions Possible, PITTSBURGH, May 28 As ... move the United States toward a,mandatory price for carbon ... provides the clearest picture yet of,the possible short-term effects ...
... PainSmart Infusion Pumps Undergo,Immediate Testing to ... MEETING, Pa., May 28 ECRI ... organization that,researches the best approaches to ... medical device alert on its Web ...
... Following are remarks by,Attorney General Michael B. Mukasey on ... Thank you, and good afternoon. I,m pleased to be ... the Justice Department is doing to,fight health care fraud. ... the Criminal Division, and everyone here for your hard,work., ...
... , , WEDNESDAY, May 28 (HealthDay News) -- Two new ... , Almost 15 percent of Americans are constipated at any ... of two reports in the May 29 issue of the ... on the efficacy of the experimental drug prucalopride on 620 ...
... provides targeted searches to Advanced Practice Clinicians, ... in the,delivery of clinical information to Advance Practice ... clinical,nurse specialists), has announced the launch of a ... )., As part of APCToday.com,s continued commitment ...
... ANGELES, May 28 Dr. Jeffrey Cummings, Medical,Director ... at UCLA,received the prestigious Ronald and Nancy Reagan ... team devote themselves to, discovering new,treatments and methods ... disorders., In his speech of acceptance at ...
Cached Medicine News:Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 2Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 3Health News:ECRI Institute Issues Priority Alert About Two Infusion Pumps 2Health News:Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide 2Health News:Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide 3Health News:Two Drugs Show Promise Against Severe Constipation 2Health News:Two Drugs Show Promise Against Severe Constipation 3Health News:APCTODAY.com and Convera(R) Launch Vertical Search Site for Advanced Practice Clinicians 2
EC+ Extra Care Bariatric Bed...
... feature folding head end and foot end deck panels ... end and foot end deck panels folded the overall ... This compact length makes storage, delivery and pick up ... not available on Model 4748B, Basic Maxi Rest bariatric ...
... I system is a unique ... combines dual width capability with ... roll" design. Specifically developed to ... patients, the easy-to-use Tri-Flex I ...
... system is a unique healthcare ... dual width capability with a ... design. Specifically developed to accommodate ... the easy-to-use Tri-Flex I system ...
Medicine Products: